Literature DB >> 8259533

Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study.

M G Conlan1, A R Folsom, A Finch, C E Davis, P Sorlie, G Marcucci, K K Wu.   

Abstract

Several coagulation proteins have been implicated as possible risk factors for the development of atherosclerotic diseases, among which are factor VIII and von Willebrand factor. As part of the Atherosclerosis Risk in Communities (ARIC) Study, a prospective study designed to assess risk factors for the development of atherosclerotic diseases, baseline measurements of factor VIII and von Willebrand factor (vWF) were performed to determine their relationship to the development of atherosclerosis. We herein report the associations of factor VIII and vWF with constitutional, lifestyle, and biochemical factors. Factor VIII and vWF were strongly correlated with each other (r = 0.73), and, therefore, had similar associations with risk factors. Mean levels of both factors were higher in women than in men, in blacks than in whites, and increased with age. In univariate analysis, both were positively associated with diabetes, body mass index, waist-to-hip ratio, serum insulin, and plasma triglycerides. Both were negatively associated with alcohol intake, educational level, physical activity (with some exceptions), and HDL-cholesterol. No correlations were observed between factor VIII or vWF and plasma LDL-cholesterol or lipoprotein(a). Although factor VIII was negatively associated with smoking in both sexes, vWF was not associated with smoking status. Most of these associations were confirmed in multivariate analysis. The strongest associations observed were of factor VIII and vWF with race and diabetes. In multivariate analysis, blacks had factor VIII and vWF levels 15 to 18 percentage points higher than whites, and diabetics had factor VIII and vWF levels 11 to 18 percentage points higher than non-diabetics.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8259533

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  78 in total

Review 1.  Pharmacological treatment of patients with peripheral arterial disease.

Authors:  Chin K Kim; Carsten M Schmalfuss; Richard S Schofield; David S Sheps
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Incidence and risk factors for cardiovascular disease in African Americans with diabetes: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Ayokanmi Adeniyi; Aaron R Folsom; Frederick L Brancati; Moise Desvorieux; James S Pankow; Herman Taylor
Journal:  J Natl Med Assoc       Date:  2002-12       Impact factor: 1.798

Review 3.  Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors:  K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 4.  Chronic Inflammatory Diseases and Endothelial Dysfunction.

Authors:  Xavier Castellon; Vera Bogdanova
Journal:  Aging Dis       Date:  2016-01-02       Impact factor: 6.745

5.  Clinical role of von Willebrand factor in acute ischemic stroke.

Authors:  Marija Menih; Miljenko Križmarić; Tanja Hojs Fabjan
Journal:  Wien Klin Wochenschr       Date:  2017-04-13       Impact factor: 1.704

Review 6.  Factoring in Factor VIII With Acute Ischemic Stroke.

Authors:  James E Siegler; Alyana Samai; Karen C Albright; Amelia K Boehme; Sheryl Martin-Schild
Journal:  Clin Appl Thromb Hemost       Date:  2015-02-10       Impact factor: 2.389

7.  A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels.

Authors:  Kevin R Viel; Deepa K Machiah; Diane M Warren; Manana Khachidze; Alfonso Buil; Karl Fernstrom; Juan C Souto; Juan M Peralta; Todd Smith; John Blangero; Sandra Porter; Stephen T Warren; Jordi Fontcuberta; Jose M Soria; W Dana Flanders; Laura Almasy; Tom E Howard
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

8.  Activated partial thromboplastin time and risk of future venous thromboembolism.

Authors:  Neil A Zakai; Tetsuya Ohira; Richard White; Aaron R Folsom; Mary Cushman
Journal:  Am J Med       Date:  2008-03       Impact factor: 4.965

9.  ABO blood group influences transfusion and survival after cardiac surgery.

Authors:  Ian J Welsby; Barbara Phillips-Bute; Joseph P Mathew; Mark F Newman; Richard Becker; Sunil Rao; Carmelo A Milano; Mark Stafford-Smith
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

10.  High factor VIII, von Willebrand factor, and fibrinogen levels and risk of venous thromboembolism in blacks and whites.

Authors:  Amanda B Payne; Connie H Miller; W Craig Hooper; Cathy Lally; Harland D Austin
Journal:  Ethn Dis       Date:  2014       Impact factor: 1.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.